ASRS 2021: A Focus on Wet Age-Related Macular Degeneration eBOOK
Focus on Macular Degenerationv2.indd
Dec 2, 2021
Focus on Macular Degenerationv2.indd
Oct 21, 2021
Most patients with neurovascular age-related macular degeneration (nAMD) would not qualify for the trials that inform currents standards of care, according to a study presented at the 39th Annual Scientific Meeting of ASRS 2021...
Oct 21, 2021
Only one-third of Medicare beneficiaries with neovascular age-related macular degeneration (nAMB) were “persistent” with anti-VEGF monotherapy treatment each year, according to a study presented at the 39th Annual Scientific...
Oct 21, 2021
Geographic disparities in access to clinical trial sites exist for neovascular age-related macular degeneration (nAMD) in the United States, according to a study presented at the 38th Annual Scientific Meeting of the American...
Oct 12, 2021
Only a third of Medicare beneficiaries were persistent with anti-VEGF monotherapy each year. Overall, two-thirds of patients treated with anti-VEGF at baseline (BL) reported similar or better visual function after 2 years....
Oct 12, 2021
There are geographic disparities in access to clinical trial sites for neovascular age-related macular degeneration (nAMD) in the US. While proximity to urban centers is beneficial for efficiency and retention of subjects, the...
Oct 12, 2021
Analysis suggests that daily self-imaging generated images of satisfactory quality for human grading and automated analysis of fluid volume over time permitting a novel paradigm of monitoring. Home OCT may allow personalized...
Oct 12, 2021
The average patient with neovascular age-related macular degeneration (nvAMD) would not qualify for the trials that determine current standards of care. Clinical trial methodology could be to blame for real-world patients having...
Oct 11, 2021
Data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular edema (DME) during the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting and will be presented an encore presentation...
Oct 11, 2021
Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema. Investigative oral drug APX3330 has been associated with generally favorable...
Oct 11, 2021
Findings from a Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) were highlighted in two presentations during the 2021 Annual Meeting of the American...